| An SI Board Since October 1998 |
| Posts |
SubjectMarks |
Bans |
| 40 |
0 |
0
|
|
Breakthrough in Breast Cancer Detection to be Addressed in Conference Call
Open Line Conference Call on Wednesday, Oct. 14, at 4:15 p.m. EDT
RENO, Nev.--(BW HealthWire)--Oct. 8, 1998--In the spirit of National Breast Cancer Awareness Month, Lifeline BioTechnologies (OTC BB:LBTI - news) will address its breakthrough in breast cancer detection, through its proprietary product First Warning(tm).
The Company has developed a non-invasive, pain-free test for detecting the formation of extremely early stage breast lesions, particularly in younger women.
Dr. Kevin Buckman, Lifelines' CEO and Jim Holmes, Lifelines' CFO will be available to discuss the latest company developments and to present a long-term strategic outlook for Lifeline BioTechnologies as part of an ''open line'' teleconference scheduled for Wednesday Oct. 14, beginning shortly after the market close at 4:15 p.m. EDT (3:15 p.m. Central/2:15 p.m. Mountain/1:15 p.m. Pacific).
Among the topics to be addressed by Dr. Buckman will be Lifeline's recent advancements as well as comparisons with other breast cancer detection methods, including technology from Trex Medical Corporation (Amex: TXM - news) and Computerized Thermal Imaging, Inc. (OTC BBB:COII).
All current and prospective shareholders, institutional portfolio managers, investment bankers, securities analysts, members of the brokerage community, representatives of the trade and general business media, and other interested parties are welcome to participate in this conference call.
To take part in the teleconference, participants must register through M&A West at 650/588-2678 or send in a request on Lifeline BioTechnologies' web site, www.lbti.com.
Lifeline BioTechnologies, Inc. (Lifeline) has developed a non-invasive test for early breast cancer detection. The test is incorporated into a proprietary product called First Warning(tm). In preliminary pilot studies, First Warning(tm) demonstrated great promise in detecting formation of extremely early stage breast lesions, particularly in younger women. The second product division under Lifeline BioTechnologies is a line of nutritional food supplements packaged and sold under the tradename NATURE'S CREATIONS. These supplements are marketed and directed towards people afflicted with degenerative diseases that are commonly found in the aging population. These diseases include cancer (breast, colon and prostate) cardiovascular, osteoporosis and mental alertness.
Financial Statements in this press release other than historical facts are ''forward-looking'' statements with the meaning of section 27A of the Securities Act of 1933, section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements are subject to the safe harbors created thereby. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results
|
